United Therapeutics Corporation
UTHR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $18,361,398 | $12,959,485 | $13,841,323 | $15,948,368 |
| - Cash | $1,340,100 | $1,593,100 | $1,899,900 | $1,697,200 |
| + Debt | $0 | $0 | $200,000 | $300,000 |
| Enterprise Value | $17,021,298 | $11,366,385 | $12,141,423 | $14,551,168 |
| Revenue | $799,500 | $798,600 | $794,400 | $735,900 |
| % Growth | 0.1% | 0.5% | 7.9% | – |
| Gross Profit | $698,600 | $711,000 | $701,900 | $660,000 |
| % Margin | 87.4% | 89% | 88.4% | 89.7% |
| EBITDA | $462,900 | $436,800 | $382,800 | $424,100 |
| % Margin | 57.9% | 54.7% | 48.2% | 57.6% |
| Net Income | $338,700 | $309,500 | $322,200 | $301,300 |
| % Margin | 42.4% | 38.8% | 40.6% | 40.9% |
| EPS Diluted | 7.16 | 6.41 | 6.63 | 6.19 |
| % Growth | 11.7% | -3.3% | 7.1% | – |
| Operating Cash Flow | $562,100 | $191,700 | $461,200 | $341,200 |
| Capital Expenditures | -$210,500 | -$62,200 | -$74,900 | -$86,700 |
| Free Cash Flow | $351,600 | $129,500 | $386,300 | $254,500 |